Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
3.100
+0.160 (5.44%)
Dec 20, 2024, 4:00 PM EST - Market closed
Tango Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 43.38 | 36.53 | 24.86 | 37.04 | 7.66 | 24.65 |
| Revenue Growth (YoY) | 15.67% | 46.93% | -32.89% | 383.83% | -68.94% | - |
| Cost of Revenue | 141.32 | 115.2 | 105.91 | 77.64 | 49.99 | 32.27 |
| Gross Profit | -97.94 | -78.67 | -81.05 | -40.59 | -42.34 | -7.63 |
| Selling, General & Admin | 41.76 | 35.5 | 30.03 | 17.6 | 9.87 | 7.54 |
| Operating Expenses | 41.76 | 35.5 | 30.03 | 17.6 | 9.87 | 7.54 |
| Operating Income | -139.7 | -114.17 | -111.07 | -58.19 | -52.2 | -15.16 |
| Interest & Investment Income | 8.31 | 6.62 | 1.46 | 0.5 | 0.11 | 0.68 |
| Other Non Operating Income (Expenses) | 5.47 | 5.94 | 1.49 | -0.25 | 0.12 | 0.38 |
| Pretax Income | -123.19 | -101.61 | -108.12 | -57.94 | -51.97 | -14.1 |
| Income Tax Expense | 0.21 | 0.13 | 0.05 | 0.29 | - | - |
| Net Income | -123.4 | -101.74 | -108.18 | -58.24 | -51.97 | -14.1 |
| Net Income to Common | -123.4 | -101.74 | -108.18 | -58.24 | -51.97 | -14.1 |
| Shares Outstanding (Basic) | 108 | 95 | 88 | 62 | 32 | 9 |
| Shares Outstanding (Diluted) | 108 | 95 | 88 | 62 | 32 | 9 |
| Shares Change (YoY) | 19.36% | 7.69% | 41.40% | 94.50% | 255.37% | - |
| EPS (Basic) | -1.14 | -1.08 | -1.23 | -0.94 | -1.63 | -1.57 |
| EPS (Diluted) | -1.14 | -1.08 | -1.23 | -0.94 | -1.63 | -1.57 |
| Free Cash Flow | -123.18 | -119.51 | -116.77 | -61.36 | 68.97 | -26.62 |
| Free Cash Flow Per Share | -1.14 | -1.26 | -1.33 | -0.99 | 2.16 | -2.96 |
| Gross Margin | -225.75% | -215.38% | - | -109.59% | - | -30.93% |
| Operating Margin | -322.01% | -312.57% | -446.79% | -157.09% | -681.82% | -61.51% |
| Profit Margin | -284.43% | -278.54% | -435.14% | -157.21% | -678.84% | -57.18% |
| Free Cash Flow Margin | -283.93% | -327.18% | -469.72% | -165.66% | 900.84% | -108.00% |
| EBITDA | -137.2 | -111.76 | -109.46 | -57.29 | -51.48 | -14.52 |
| EBITDA Margin | - | - | - | -154.67% | - | -58.90% |
| D&A For EBITDA | 2.5 | 2.42 | 1.61 | 0.9 | 0.72 | 0.64 |
| EBIT | -139.7 | -114.17 | -111.07 | -58.19 | -52.2 | -15.16 |
| EBIT Margin | - | - | - | -157.09% | - | -61.51% |
| Revenue as Reported | 43.38 | 36.53 | 24.86 | 37.04 | 7.66 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.